This clinical trial is focused on studying treatments for Stage IV non-small cell lung cancer (NSCLC), a type of lung cancer that has spread to other parts of the body. The study will explore the effectiveness and safety of different treatment combinations. One of the main treatments being tested is pembrolizumab, also known by its code name MK-3475. Pembrolizumab is a type of medication that helps the immune system fight cancer cells. Other treatments being studied in combination with pembrolizumab include patritumab deruxtecan (code name MK-1022), paclitaxel, pemetrexed disodium, carboplatin, and paclitaxel albumin-bound.

The purpose of this study is to evaluate how well these treatment combinations work and how safe they are for patients. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the participants’ response to the treatments and any side effects they may experience. The goal is to find the most effective and safe treatment options for patients with Stage IV NSCLC.

Throughout the study, researchers will assess the Objective Response Rate (ORR), which measures how well the cancer responds to the treatment. They will also track the number of participants who experience side effects and those who may need to stop the treatment due to these effects. Additionally, the study will look at the Duration of Response (DOR), Progression-Free Survival (PFS), and Overall Survival (OS) to understand the long-term benefits of the treatments. This research aims to improve treatment options for patients with advanced lung cancer.

The purpose of this study is to compare how well MK-1084 combined with MK-3475A works compared to MK-3475A combined with chemotherapy in treating this type of lung cancer, particularly in people whose tumors show a certain marker called PD-L1. The study will look at how long participants live without their cancer getting worse, how long they live overall, whether their tumors shrink or disappear, and how long any response to treatment lasts. The study will also monitor what side effects occur and whether participants need to stop treatment because of these side effects.

During the study, participants will receive one of the two treatment combinations. They will have regular check-ups where doctors will examine them, take blood samples, and perform scans to see how the cancer is responding to treatment. Participants will also be asked to complete questionnaires about their quality of life, including questions about breathing difficulties, coughing, and chest pain. The doctors will track any health problems that occur during treatment and measure changes in symptoms and overall well-being throughout the study.

The purpose of this research is to compare two different approaches to planning radiation treatment. One approach uses functional lung imaging that shows blood flow patterns in the lungs, while the other uses traditional anatomical planning. The study aims to determine if using the blood flow imaging method results in fewer breathing problems or lung damage after radiation treatment.

During the study, participants will receive their prescribed radiation therapy and will have follow-up visits over one year to monitor their progress. The imaging agent will be used to create detailed pictures of their lungs before treatment and again three months after treatment. Doctors will check for any breathing difficulties or lung-related side effects throughout the study period. The maximum amount of the imaging agent used will be 200 MBq per scan, with a total of 400 MBq over two days.

The purpose of this study is to determine how effective the combination of these medications is at eliminating cancer cells before surgery. The treatment is given in two phases – before surgery (called neoadjuvant treatment) and after surgery (called adjuvant treatment). Before surgery, patients receive both medications. After surgery, all patients receive zimberelimab, and some patients may also continue receiving sacituzumab govitecan.

During the study, patients will receive regular medical examinations and various tests to monitor their health and how well the treatment is working. The treatment period may last up to 54 weeks. Zimberelimab is given at doses up to 360 milligrams, while sacituzumab govitecan is given based on the patient’s body weight, up to 10 milligrams per kilogram of body weight.

The purpose of this study is to evaluate the effectiveness of a drug called tarlatamab. This medication is an intravenous infusion, meaning it is delivered directly into a vein through a liquid solution. Participants in the trial will receive this treatment to see how it influences how long patients live and how the cancer responds to the medicine.

During the study, participants will continue to take their regular dose of osimertinib and will also begin taking febuxostat. To see how well the drugs are working, researchers will measure the amount of the medication in both the blood and the cerebrospinal fluid, which is the clear liquid that surrounds the brain and spinal cord. These measurements will be taken before and after the addition of the second medication to compare the levels.

The purpose of this study is to measure how much the uptake of the tracer in tumors and organs varies between two scans that are done close together in time. During the study, participants will receive the tracer and undergo PET scans, which are special imaging tests that create pictures of the inside of the body. The scans will be repeated within a short time period to compare the results and see how consistent the imaging measurements are.

The study looks at whether the amount of tracer that appears in the tumor stays the same or changes between the two scans. This information helps researchers understand how reliable this imaging method is for looking at lung tumors. Participants must have at least one tumor that measures two centimeters or larger to be part of this research.

The purpose of this study is to collect detailed information about lung structure and function before and after radiotherapy treatment. By comparing images taken before treatment starts with images taken after treatment is completed, researchers want to see what changes happen in the lungs as a result of the radiotherapy. These changes will be looked at by examining ventilation maps, which are special images that show how air moves through different parts of the lungs. The study aims to identify areas where the lung function may have improved or worsened due to the radiation treatment.

During the study, participants will undergo scanning sessions where they will breathe in the xenon and oxygen gas mixture while lying in the CT scanner. The scans will capture images of the lungs while the gas is present, allowing doctors to see which areas of the lungs are receiving good airflow and which areas may not be working as well. Participants will need to hold their breath for short periods of about three seconds during the scanning. The study will involve scans done before the radiotherapy begins and again after the radiotherapy treatment has finished, so that doctors can measure and compare any changes that have occurred in lung function and tissue structure.

Participants in the study will receive either a high dose of Dexamethasone, calculated as 1 milligram per kilogram of body weight, or a lower dose of 8 milligrams in total. The medication will be given intravenously, which means it will be administered directly into a vein, after the patient has been put under anesthesia for the surgery. Some participants will receive a placebo instead of Dexamethasone. The study will monitor pain levels, especially when coughing, and other factors like the use of additional pain relief medications, nausea, and the length of hospital stay after surgery.

The trial will also look at other outcomes, such as the quality of recovery, any complications within 30 days after surgery, and the overall experience of the patients during their recovery. The study is expected to continue until October 2026, with recruitment starting in June 2025. The findings from this trial could help improve pain management strategies for patients undergoing lung surgery.

The purpose of the study is to evaluate how effective this combination is in treating brain metastases in patients who have already received certain other treatments. Participants in the study will receive the medications through an infusion, which means the drugs are delivered directly into the bloodstream. The study will monitor the effects of the treatment over a period of time, with regular assessments using MRI scans to check the response of the brain metastases to the treatment.

Throughout the study, the safety of the treatment will be closely monitored, and participants will have regular check-ups to ensure they are responding well to the treatment. The study aims to provide valuable information on whether this combination of medications can be an effective treatment option for patients with NSCLC that has spread to the brain.

The purpose of this study is to compare the effects of continuing standard immunotherapy with a reduced dose of the same treatment. The medications being studied include Pembrolizumab, Durvalumab, Avelumab, Nivolumab, Dostarlimab, Atezolizumab, and Cemiplimab. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. Some patients will receive the standard dose of these medications, while others will receive a reduced dose every three months.

The study will last for up to three years, during which time patients will continue to receive their assigned treatment. The main goal is to see if the reduced dose is as effective as the standard dose in keeping the cancer from getting worse. Patients will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study will also look at other factors, such as the quality of life and any side effects experienced by the patients. This research aims to find the best way to use immunotherapy to treat cancer effectively while minimizing side effects.

The purpose of the study is to explore how well Patritumab Deruxtecan works in patients whose cancer has spread to other parts of the body or is locally advanced, meaning it has grown but not spread far. Participants in the study will receive the treatment and be monitored over time to see how their cancer responds. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the new treatment.

Throughout the study, doctors will check the size of the tumors and how long the treatment keeps the cancer from getting worse. They will also look at how long patients live after starting the treatment and any side effects they might experience. The study aims to provide more information about the potential benefits and safety of Patritumab Deruxtecan for treating this specific type of lung cancer.

The purpose of this study is to assess how patients with NSCLC respond to this combination of treatments before undergoing surgery intended to remove the cancer. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will follow a specific schedule where patients will receive the treatment over a period of time before their planned surgery.

Throughout the study, researchers will monitor the response of the cancer to the treatment by looking at changes in tumor size and other indicators. The study will also track the overall health and survival of the participants for a period after the treatment and surgery. This research aims to provide insights into how well this combination of drugs works in treating NSCLC and to help predict which patients might benefit the most from this approach.

Participants in this study are those whose cancer has not worsened after receiving a specific type of treatment called chemoradiation therapy, which combines chemotherapy and radiation. The study will involve regular monitoring of the participants’ health and the progression of their cancer over a period of time. The treatment will be administered through an infusion, which means the medication is given directly into the bloodstream through a vein. The study aims to determine if the combination of Durvalumab and Domvanalimab can help improve the time patients live without their cancer getting worse.

Throughout the study, participants will receive either the combination of Durvalumab and Domvanalimab or Durvalumab with a placebo. The study will last for a set period, during which participants will be closely monitored by healthcare professionals. The goal is to gather information on how well the treatment works and its safety. This research could potentially lead to new treatment options for patients with advanced NSCLC, providing hope for better management of this challenging condition.

The purpose of this study is to see how effective the combination of niraparib and anti-PD-L1 antibodies is in treating patients with this specific type of lung cancer. Patients who participate in the study will receive the treatment over a period of time, and their health will be monitored to see how the cancer responds. The study will also compare the effects of the treatment with a placebo to better understand its benefits.

Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein, and they will also take niraparib in tablet form. The study aims to provide more information on how well this combination works in preventing the cancer from getting worse and improving overall survival rates. The results will help determine if this treatment approach can be a beneficial option for patients with this type of lung cancer.

The purpose of the study is to explore how digital health solutions can impact health outcomes and the use of healthcare resources for people receiving systemic treatment, which is a type of treatment that affects the entire body. In the first group, the study aims to show how a digital patient monitoring system can help manage symptoms for those receiving atezolizumab. In the second group, the study will look at how feasible it is to combine this digital monitoring with atezolizumab treatment administered at home.

Participants in the study will receive either atezolizumab or a placebo. The study will monitor various aspects of health, including symptom management and the number of hospital visits. The trial will also assess the safety and side effects of atezolizumab when used in combination with digital health tools. The study is expected to continue until 2025, with participants being observed over a period of time to gather comprehensive data on the treatment’s effectiveness and impact on quality of life.

The study is designed to compare two groups of patients: those who receive the chemotherapy treatment and those who do not, to see if the treatment helps in extending the time patients remain free from cancer. The chemotherapy treatment is given in cycles, with each cycle lasting a few weeks, and the total treatment period can last up to 16 weeks. The study aims to personalize patient care by using a special test called the 14-Gene Prognostic Assay, which helps determine the risk level of cancer returning based on the genetic makeup of the tumor.

Participants in the study will be monitored over time to track their health and any signs of cancer returning. The study will help researchers understand if using chemotherapy after surgery can improve outcomes for patients with high or intermediate risk of cancer recurrence. This information could lead to better treatment strategies for patients with early-stage non-squamous NSCLC in the future.

Participants in the study will receive the treatment as a solution through an infusion, which means it will be administered directly into the bloodstream. The study will be conducted in different parts, each focusing on different aspects of the treatment, such as its safety and how well it works against the cancer. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatment. The study will also monitor how the body processes the treatment and any potential side effects that may occur.

The trial will take place over several years, allowing researchers to gather comprehensive data on the treatment’s impact on the disease. Throughout the study, participants will undergo regular check-ups and tests to assess their health and the progress of the treatment. The ultimate goal is to determine if Rilvegostomig can be a safe and effective option for treating advanced stages of Non-small Cell Lung Cancer.

Participants in the study will be randomly assigned to receive either Pralsetinib or one of the standard chemotherapy treatments. The study will monitor the participants over time to see how their cancer responds to the treatment. This includes checking if the cancer shrinks, stays the same, or grows. The study will also look at how long participants live and any side effects they experience. The treatment period can vary, with some treatments lasting up to 104 weeks.

The study is open-label, meaning both the participants and the researchers know which treatment is being given. Participants will receive their treatment through different methods, such as IV infusion or taking capsules orally, depending on the medication. The study aims to provide valuable information on the effectiveness and safety of Pralsetinib compared to the standard care options for patients with this specific type of lung cancer.

The purpose of the study is to evaluate how well PC14586 works in treating these specific types of tumors. Participants in the study will receive the medication and be monitored for its effects on their cancer. The study will also look at how safe and tolerable the medication is for patients, as well as how the body processes the drug. This will involve regular check-ups and assessments by healthcare professionals to ensure the well-being of the participants.

Throughout the study, participants will undergo various tests and evaluations to track the progress of their treatment. These may include imaging tests to see how the tumors respond to the medication and regular health assessments to monitor any side effects. The study aims to gather important information that could lead to new treatment options for patients with these specific types of cancer.

The purpose of this study is to evaluate how safe it is to use Lanreotide in combination with Metformin in patients with these specific types of tumors. Participants in the study will receive both medications and will be monitored for any side effects or changes in their condition. The study is designed to observe how the body responds to this combination of treatments over a period of time. Participants will receive regular check-ups, including physical exams and laboratory tests, to ensure their safety and to gather information about the treatment’s effects.

This study is open-label, meaning that both the participants and the researchers know which treatments are being administered. It is a pilot study, which means it is an initial, smaller-scale study to gather preliminary data. The study will help researchers understand the potential benefits and risks of using Lanreotide and Metformin together in treating advanced gastrointestinal or lung carcinoids. The information gathered from this study may contribute to future research and treatment options for these types of tumors.

The main goal of the study is to assess the safety and how well patients tolerate ATL001 as a treatment. Participants in the study will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will monitor patients over time to see how their cancer responds to the treatment and to check for any side effects. The study will also compare the effects of the treatment with those of a placebo.

Throughout the study, patients will have regular check-ups to track their health and the progress of their cancer. The study will measure changes in tumor size and overall health outcomes, such as how long patients live without their cancer getting worse. This research aims to provide new insights into treating non-small cell lung cancer and potentially offer new options for patients with this type of cancer.

The purpose of the study is to assess the safety of continuing osimertinib treatment while patients undergo radiation therapy. The study will monitor for any side effects that may occur during and after the combination of these treatments. Patients will take osimertinib in the form of film-coated tablets, and the study will observe how well patients tolerate the treatment and how it affects their cancer.

Throughout the study, patients will receive regular check-ups to monitor their health and the progress of their cancer. The study aims to understand how well the combination of osimertinib and radiation therapy works in controlling the cancer and improving patients’ quality of life. The trial will also look at how long patients live without their cancer getting worse and how long they live overall. The study is expected to continue until the end of 2026.

The purpose of the study is to find the best dose of the non-radioactive version of Patritumab Deruxtecan to use alongside the radioactive version for imaging purposes. This will help doctors get a clear picture of how the medicine is distributed in the body. The study will involve several groups of patients, each receiving different amounts of the non-radioactive medicine. Doctors will then use a type of scan called PET/CT to see how well the medicine is working in the body. This scan combines two imaging techniques to provide detailed pictures of the inside of the body.

Throughout the study, doctors will also measure how much of the radioactive medicine is taken up by the tumors. This is done both visually and by calculating a value known as the standardized uptake value (SUV), which helps in understanding how the tumors are responding to the treatment. The study aims to provide valuable information that could improve the way this type of lung cancer is treated in the future.

The purpose of the study is to find the best dose of acetazolamide when used with these treatments. Participants will be divided into two groups based on their type of lung cancer. One group will receive acetazolamide with radiochemotherapy, which includes platinum-based chemotherapy and a drug called etoposide. The other group will receive acetazolamide with radioimmunotherapy. The study will last several weeks, and participants will be monitored for six months after their treatment ends to check for any side effects and to see how well the treatment works.

Throughout the study, the safety of acetazolamide will be closely monitored. Researchers will also assess how well the cancer responds to the treatment, using methods like RECIST and PERCIST evaluations, which help measure changes in tumor size and activity. Additionally, the study will look at factors that might predict how well a patient responds to acetazolamide, as well as overall survival and quality of life over a period of 24 months.

The purpose of the study is to evaluate and compare the effectiveness of the PD-1/PD-L1 inhibitor treatment with or without the addition of the UV1 vaccine in patients with advanced stages of NSCLC. Participants in the study will receive either the PD-1/PD-L1 inhibitor alone or in combination with the UV1 vaccine. The study will monitor the participants over a period to assess how well the treatments work and to ensure their safety.

Throughout the study, participants will receive the treatments as an injection under the skin, known as intradermal use. The study aims to gather information on how long patients live without the cancer getting worse, known as progression-free survival, as well as other outcomes like overall survival and response to treatment. The study is expected to continue until 2027, providing valuable insights into the potential benefits of combining the UV1 vaccine with standard cancer treatments.

The purpose of the study is to see how well this combination treatment works in keeping the cancer from getting worse over a period of six months. Participants in the study will receive atezolizumab through an intravenous infusion, which means it is given directly into a vein. The dendritic cell vaccine is administered through an injection into the skin. Some participants may receive a placebo instead of the actual treatment to help researchers compare the effects.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of the cancer. The study aims to understand how long the treatment can keep the cancer from progressing and how it affects overall survival. The results will help determine if this combination of atezolizumab and the dendritic cell vaccine is an effective maintenance treatment for patients with ES-SCLC.